Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Phase 1 Terminated

3 enrolled 5 charts

DermatologicGastrointestinalLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Colonic Neoplasms, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mycosis Fungoides, Rectal Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT04185311 2023-08-15

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Phase 1 Terminated

6 enrolled

Breast

Breast Carcinoma In Situ, Triple Negative Breast Neoplasms

NCT01940809 2022-03-10

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

15 enrolled

Dermatologic

Melanoma

NCT03425461 2021-04-02

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Phase 1 Terminated

6 enrolled

Dermatologic

Melanoma

NCT02892734 2020-07-16

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Phase 2 Terminated

3 enrolled 11 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01970527 2020-02-13

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Phase 2 Terminated

23 enrolled 13 charts

Dermatologic

Melanoma

NCT00039091 2018-09-05

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

Phase 1 Terminated

26 enrolled

DermatologicGynecologicMyeloidOther hematologic neoplasmThoracic

Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Melanoma, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT01730157 2016-03-10

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Phase EARLY_PHASE1 Terminated

6 enrolled

Dermatologic

Uveal Melanoma